p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors.
We examined p53 protein expression, p53 gene mutation, proliferating cell nuclear antigen (PCNA), and argyrophilic nuclear organizer regions (AgNOR), in 30 patients with surgically-treated thymic tumors (26 thymoma and 4 thymic carcinoma cases). p53 expression ratio with DO-1 was divided as p53 negative (0% positivity), low expressor (<10% positivity), high expressor (>10% positivity). The incidence of p53 low and high expressor in thymoma were 19% (5/26) and 8% (2/26), respectively. p53 immunopositivity in thymoma was significantly correlated with PCNA labeling index (LI). p53 expression ratio in invasive thymoma (33%) tended to be higher than that in non-invasive thymoma (18%). p53 expression was detected in one of the thymic carcinoma. There were no p53 gene mutations in 15 invasive thymoma, although one of four (25%) thymic carcinomas showed two point mutations. p53 gene alterations seem to be associated with malignant activity of tumor cells, and therefore detection of p53 gene mutations is useful as a diagnostic factor.
Oyama
T
T
VCC, 649 Medical Research Building II, Carbone LAB (648), Nashville, TN 37232-6838, USA.
Osaki
T
T
Mitsudomi
T
T
Ogawa
R
R
Nakanishi
R
R
Sugio
K
K
Yasumoto
K
K
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009697:Nucleolus Organizer Region / Q000473:pathology*; D017354:Point Mutation; D011237:Predictive Value of Tests; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D013945:Thymoma / Q000737:chemistry / Q000473:pathology*; D013953:Thymus Neoplasms / Q000737:chemistry / Q000473:pathology*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics*
D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53